Y-27632 dihydrochloride: Selective ROCK1/2 Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a potent, cell-permeable small-molecule inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, exhibiting IC₅₀ values of 140 nM and a K_i of 300 nM respectively, with >200-fold selectivity over related kinases (ApexBio A3008, [product page]). It disrupts Rho-mediated stress fiber formation and modulates cell cycle progression from G1 to S phase in diverse cell types ([Cell Death Dis. 2025;16:660](https://doi.org/10.1038/s41419-025-07980-8)). Y-27632 is widely used in studies of stem cell viability, tumor invasion, and cytoskeletal dynamics. The compound offers high aqueous solubility and robust performance in both in vitro and in vivo assays. Its specificity enables precise dissection of the Rho/ROCK pathway without substantial off-target effects when used at recommended concentrations.

Biological Rationale

The Rho/ROCK pathway is central to cytoskeletal regulation, cell migration, proliferation, and invasion across multiple biological systems (Dian et al., 2025). ROCK1 and ROCK2 are serine/threonine kinases that phosphorylate downstream effectors, including myosin light chain (MLC), leading to actin stress fiber formation. Dysregulation of Rho/ROCK signaling contributes to cancer progression, metastasis, and aberrant cellular contractility. Y-27632 dihydrochloride has become a reference standard for probing these processes due to its high selectivity and well-characterized molecular target profile (see review).

Compared to other kinase inhibitors, Y-27632's specificity for ROCK1/2 minimizes confounding off-target effects, enabling mechanistic studies of Rho-dependent events. For example, in lung and prostate cancer models, Rho/ROCK signaling promotes tumor cell invasion and survival, linking pathway inhibition to reduced metastatic potential (Dian et al., 2025).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a reversible ATP-competitive inhibitor that binds the catalytic domain of ROCK1 and ROCK2, blocking substrate phosphorylation (ApexBio). At concentrations ≥140 nM, Y-27632 effectively inhibits ROCK1 activity, while a K_i of 300 nM is reported for ROCK2. The compound exhibits more than 200-fold selectivity over closely related kinases—including PKC, PKA, MLCK, and PAK—when assessed in competitive kinase panels.

Y-27632 prevents Rho-induced formation of actin stress fibers, reduces cellular contractility, and interferes with cytokinesis. This leads to altered cell morphology, suppressed migration, and impaired cell cycle progression from G1 to S phase. The compound also disrupts endo-lysosomal trafficking and vesicle dynamics, extending its functional reach in cell biology (see endo-lysosomal review; this article further details cytoskeletal and oncogenic mechanisms).

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 with an IC₅₀ of 140 nM and ROCK2 with a K_i of 300 nM, showing >200-fold selectivity versus PKC, PKA, MLCK, and PAK (ApexBio technical data).
• In vitro, Y-27632 reduces proliferation of prostatic smooth muscle cells in a dose-dependent manner (1–10 μM, 24–72 h) (Dian et al., 2025).
• In mouse models, Y-27632 administration (10–30 mg/kg, intraperitoneal) decreases tumor invasion and metastasis without overt toxicity (Dian et al., 2025).
• Y-27632 enhances human stem cell viability and plating efficiency (>90% survival at 10 μM, 24 h post-thawing) in pluripotent stem cell culture (see workflow guide; this article provides updated solubility ranges and storage protocols).
• Y-27632 is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water at 25°C, with enhanced solubility at 37°C or after ultrasonication (ApexBio).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is extensively used in:

• Stem cell research: Enhancing survival and proliferation during passaging and cryopreservation.
• Cancer biology: Inhibiting ROCK-driven tumor cell migration, invasion, and metastasis.
• Cytoskeletal studies: Dissecting actin filament dynamics and cell contractility.
• Endo-lysosomal trafficking: Modulating vesicle movement and neurodegenerative disease model pathways (see neurodegeneration review; this article expands on cytoskeletal and cancer contexts).

Limits:

• Y-27632 does not inhibit RhoA directly; it targets downstream ROCK kinases.
• Long-term storage of solutions (especially in aqueous media) is not recommended due to hydrolytic instability.
• At concentrations >50 μM, off-target effects may increase and cell viability may decrease.

Common Pitfalls or Misconceptions

• Misconception: Y-27632 is a pan-kinase inhibitor.
  Fact: Y-27632 is highly selective for ROCK1/2, with >200-fold selectivity over other kinases.
• Misconception: Y-27632 directly inhibits Rho GTPases.
  Fact: It acts downstream, inhibiting ROCK1/2 but not RhoA or related GTPases.
• Pitfall: Using outdated solubility values may lead to precipitation or inaccurate dosing.
  Fact: Confirm solubility at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water.
• Pitfall: Assuming universal cytoprotective effects.
  Fact: Y-27632 enhances stem cell survival but may reduce proliferation in other cell types (e.g., smooth muscle).
• Pitfall: Prolonged storage of aqueous solutions.
  Fact: Store solid compound desiccated at 4°C or below; freshly prepare solutions for use.

Workflow Integration & Parameters

For standard cell culture, Y-27632 can be dissolved in DMSO at concentrations up to 111.2 mg/mL. For aqueous applications, use freshly prepared solutions at 10–50 μM, adjusting for cell type and endpoint. Solubility may be enhanced by warming to 37°C or brief ultrasonication. Stock solutions (10–100 mM in DMSO) may be stored at −20°C for several months, but repeated freeze–thaw cycles should be avoided. The solid compound is stable when stored desiccated at 4°C or below.

In vivo, dosing regimens commonly range from 10–30 mg/kg (intraperitoneal), with monitoring for toxicity and off-target effects. For stem cell applications, supplementing media with 10 μM Y-27632 for 24–48 h post-thaw or passage is recommended, followed by removal to avoid long-term effects. For cancer invasion assays, titrate concentrations to 10–50 μM based on cell line sensitivity and validate inhibition by phospho-MLC or cytoskeletal staining.

For more advanced applications, see this article on extracellular vesicle studies, which focuses on Y-27632's role in vesicle release and tumor invasion. The present article details updated solubility, specificity, and workflow integration for cytoskeletal and cancer assay optimization.

Conclusion & Outlook

Y-27632 dihydrochloride remains a gold-standard selective ROCK1/2 inhibitor for dissecting Rho/ROCK signaling in cell biology, stem cell, and cancer research. Its nanomolar potency, high aqueous solubility, and robust selectivity enable precise investigations of cytoskeletal organization, cell proliferation, and tumor invasion. Proper storage and dosing are critical for reproducible results. Ongoing research continues to expand the application scope of Y-27632, particularly in tumor microenvironment modulation and regenerative medicine. For detailed specifications and ordering, consult the ApexBio A3008 product page.